Trials / Withdrawn
WithdrawnNCT02580253
Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation
Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, open-label, controlled study that will explore the efficacy of individualized adjuvant chemotherapy based on the adenosine triphosphate tumor chemosensitivity assay for patients with hepatocellular carcinoma after liver transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Individualized Chemotherapy | Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin) |
| DRUG | mFOLFOX6 | Oxaliplatin,Fluorouracil |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2018-11-01
- Completion
- 2018-12-01
- First posted
- 2015-10-20
- Last updated
- 2020-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02580253. Inclusion in this directory is not an endorsement.